AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00500461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
Study NCT02748876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: His-Ventricular (HV) optimisation
Description: Optimisation of atrioventricular pacing interval
Study NCT01899638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 mcg
Description: Combination in high dose
Study NCT01899638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg
Description: Combination in low dose
Study NCT01899638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 125 mcg
Description: LAMA mono in high dose
Study NCT01899638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 mcg
Description: LAMA mono in low dose
Study NCT01899638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 25 mcg
Description: LABA mono
Study NCT03137953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation
Description: The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
Study NCT03137953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiological Imaging
Description: Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
Study NCT03061292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Nerve Block
Study NCT03061292 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Without Pectoral Nerve Block
Study NCT01607125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
Study NCT01607125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, orally, once daily for 13 to 14 days
Study NCT02308267 — intervention group
Intervention type: OTHER
Intervention: Lung explants
Description: Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
Study NCT02308267 — intervention group
Intervention type: OTHER
Intervention: Sputum, nasal fluid and serum
Description: Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
Study NCT02308267 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
Study NCT01633840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elemental E028 with added food allergens
Description: Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
Study NCT01633840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elemental E028
Description: Elemental E028 with no added food allergens
Study NCT04704713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Study NCT04704713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02288299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive mechanical ventilation
Description: instrumental increase of inspiratory capacity and cough
Study NCT00976157 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy BAL
Description: The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
Study NCT04345692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
Study NCT02962245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: berberine
Study NCT03385564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study NCT02962245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular treatment
Description: such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
Study NCT02962245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regular treatment
Description: such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
Study NCT01221818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 50mg single dose or matching placebo
Study NCT01433042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Description: capsule endoscopy procedure
Study NCT04290572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin capsules
Description: Jelly capsules of isotretinoin
Study NCT03565341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4
Description: PiQo4 Laser System for treatment of Melasma
Study NCT02250469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with the Axium SCS system
Study NCT02250469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with the Medtronic SCS System
Study NCT04220580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: 3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
Study NCT00099502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 250mcg administered s.c. every other day
Study NCT00099502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 500mcg administered s.c. every other day
Study NCT00099502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Description: 20 mg administered s.c. once daily.
Study NCT01840813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
Study NCT01840813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: It is a placebo group
Study NCT02489149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sector interventions
Description: * Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights.
Study NCT02489149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Comparator: Conventional approach of current public food and nutrition policies.
Study NCT00777595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single therapeutic dose
Study NCT00777595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single supratherapeutic dose
Study NCT00777595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled solution, single dose of placebo
Study NCT00777595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablet, oral, 400mg, single dose
Study NCT04054921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: PTG-300 is a hepcidin Mimetic
Study NCT03804892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: Participants undergo a 5 minute body scan to determine their body composition.
Study NCT03804892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Body Composition
Description: Participants undergo a 5 minute body scan to determine their body composition.
Study NCT03804892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximal aerobic fitness test
Description: Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
Study NCT01113931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyline Hyclate tablet
Description: 200 mg tablet, once daily for 7 days
Study NCT01113931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibramycin (doxycyline hyclate) capsule
Description: 100 mg capsule, twice daily for 7 days, over-encapsulated
Study NCT02374463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMBI
Description: Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
Study NCT01221818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 100mg single dose or matching placebo
Study NCT01221818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 200mg single dose or matching placebo
Study NCT01221818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 400mg single dose or matching placebo
Study NCT01221818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 600 mg single dose or matching placebo
Study NCT04117412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Same participants will undergo different one bout of exercise protocols
Study NCT01909609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAP Documents
Study NCT01909609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Survival Guide
Study NCT01909609 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Parent Survival Guide
Study NCT03406364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG005
Description: Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy.
Study NCT01082978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic (USB) Portable Health File
Description: Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
Study NCT01082978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paper Portable Health File
Description: Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
Study NCT02726126 — intervention group
Intervention type: DRUG
Intervention: Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy
Study NCT02374463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
Study NCT00967226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
Study NCT00967226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 1.0 mg/kg orally, 2 per day 4-6 months
Study NCT03804892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Maximal aerobic fitness test
Description: Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
Study NCT03804892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participants will undergo an OGTT to determine insulin sensitivity.
Study NCT03804892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Participants will undergo an OGTT to determine insulin sensitivity.
Study NCT03804892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
Study NCT03804892 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle biopsy
Description: Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
Study NCT03804892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
Study NCT03804892 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
Study NCT02656394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GL101
Description: Topical Gel
Study NCT02656394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical gel
Study NCT02556281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is done for patient with colorectal cancer
Study NCT01489865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 and mFOLFOX-6
Description: ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
Study NCT04204850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1000/Ca0
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1000/Ca0
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1000/Ca500
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1000/Ca500
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1000/Ca1000
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1000/Ca1000
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
Study NCT02095392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: all participants consume two weeks before intervention the beverage without phosphate and calcium
Study NCT00190333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram
Study NCT04544735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Physical Therapy and Coping Skills Training
Description: The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
Study NCT00451958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 80 mg / Degarelix 80 mg
Study NCT00451958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 160 mg / Degarelix 160 mg
Study NCT00451958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide 7.5 mg / Degarelix 80 mg
Study NCT00451958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide 7.5 mg / Degarelix 160 mg
Study NCT01968538 — intervention group
Intervention type: RADIATION
Intervention: Radiation Therapy
Study NCT01777048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids Supplementation
Study NCT01777048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Placebo
Description: Placebo capsules manufactured to mimic Omega-3 capsules
Study NCT00932035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node dissection
Description: Undergo reverse mapping-guided axillary lymph node dissection